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Abstract
The extracellular matrix (ECM) is the non-cellular component of the tissues 
of our organism. It is the dynamic element that maintains a biochemical structure 
capable of supporting the organization and architecture of the tissue constituents. 
The diversity of ECM’s constituents gives it the biochemical and biophysical 
properties necessary to regulate its behavior and differentiation. ECM has an 
important role in the biology of cancer cell development and progression. Human 
papillomavirus infection (HPV) is the principal etiological agent of the most 
common sexually transmitted diseases. It is a virus that can cause lesions precur-
sors of epithelial squamous and glandular tumors. Type 16 (HPV16) is the leading 
cause of pre-malignant lesions and invasive cancers in these tissues. This work will 
focus on HPV infection to understand the role of ECM in the invasion, spread, and 
pathogenesis of the lesions caused by this virus. Cancer is no longer considered a 
pathology explained only by uncontrolled proliferation and apoptosis but also by 
the deregulation of the microenvironment.
The in-depth knowledge of ECM dynamics and its complexity is central and 
promising, specifically in developing new targeted therapies.
Keywords: Extracellular matrix, human papillomavirus, heparan sulfate 
proteoglycans, metalloproteinases, heparanase
1. Introduction
The extracellular matrix (ECM) can be defined as a three-dimensional, non-
cellular macromolecular network made of collagen, proteoglycans, elastin, fibro-
nectin, laminins, and other glycoproteins structural support for the organization 
of cellular constituents. It is known to be a physiologically active component of 
living tissue. The various parts of the matrix bind to each other and cell adhe-
sion receptors, forming a complex network on which cells rely in all tissues and 
organs. Through transduction of extracellular signals originating from the ECM, 
cell surface receptors regulate diverse cellular functions such as survival, growth, 
migration, and differentiation and are vital for homeostasis maintenance [1, 2].
Each organ has a unique combination of elements in its constitution so that the 
specific function of the tissue itself can be fulfilled. This unique composition arises 
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from biophysical and biochemical feedback between cellular components and the 
microenvironment, where they are inserted during the genesis of the tissue. The 
ECM continuously undergoes remodeling mediated by different decomposition 
enzymes, the proteinases being a highly dynamic structure. The balance between 
ECM degradation and secretion, orchestrated by ECM-modifying cells, is respon-
sible for tensional homeostasis and organ-specific properties such as elasticity and 
compressibility [2–6].
In vitro, most animal cells have been shown to remain viable only when adher-
ent to a substrate. Thus, the cell relies heavily on its sense of touch to survive by 
adhering and spatially interacting with the surrounding ECM- the concept of 
anoikis. The ability to attach and communicate with its environment is responsible 
for several growth factor receptors, and adhesion molecules arranged along the cell 
membrane, namely integrins. Indeed, cells have been shown to translate signals 
from the ECM to coordinate crucial morphological organization and signal events 
by regulating gene transcription. A cell converts external mechanical stimuli into a 
downstream intracellular chemical signal. This process is known as mechanotrans-
duction. The sensitivity with which cells respond to biophysical and biochemical 
signals from the ECM demonstrates the importance of tissue homeostasis in 
maintaining healthy host cells.
Consequently, dysregulation of ECM remodeling has been shown to contribute 
significantly to cellular evolution through various fibrotic conditions, character-
ized by excessive ECM deposition and increased ECM stiffness. Due to increased 
interstitial pressure, irreversible loss of tissue homeostasis has been linked to an 
increased risk for various pathological conditions such as osteoarthritis, cardiovas-
cular disease, and cancer [3, 4, 6–10].
2. ECM constitution
Various proteins that constitute the ECM result in different structures and 
properties. The main components of ECM include collagen, proteoglycans, lam-
inin, and fibronectin. As each structure has a function, different subtypes and 
combinations of ECM molecules confer different functions essential to the correct 
functioning of the whole organism, Figure 1 [11, 12].
Figure 1. 
ECM components and their organization. Organization of the different collagens, proteoglycans (HPSG), 
laminins, and fibronectin in the basement membrane and the extracellular matrix. In the basement 
membrane, laminin is attached to the cell, forming a fibrillar network. It is then linked to the type IV collagen 
network through nidogen and proteoglycans such as perlecan and agrinin. The different proteoglycans hold the 
fibrils together to form a collagen fiber. Fibronectin is bound to the cell by integrins and syndecans.
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2.1 Collagen
Collagen is the basis of ECM architecture, is the most significant functional  
component, and the most abundant protein in human tissue. It can be classified into 
fibrillar (I-III, V, and XI) and non-fibrillar. Collagen fibers give ECM its tensile strength 
by limiting tissue distensibility. Collagens are trimeric molecules composed of three 
α-polypeptide chains that contain the sequence repeat (G-X-Y). This repeat allows the 
formation of a triple helix that gives the characteristic structure of this superfamily, 
Figure 1. Currently, there are 28 unique subtypes of collagen discovered. Each member 
of the collagen family has at least one triple helix domain. Most collagens bind to and 
interact with several ECM proteins forming supramolecular aggregates [3, 6, 8, 11].
Fibrillar collagens form fibrous structures often found in tendons, cartilage, 
skin, and cornea. Each collagen fiber is made up of several collagen subtypes in 
response to their tissue location.
Fundamentally we can define four classes of collagens:
1. Fibril-forming collagens (I, II, III, V, XI, XXVI, XXVII)
2. Fibril-associated collagens with interrupted helices (FACITs) (IX, XII, XIV, 
XVI, XIX, XX, XXI, XXII, XXIV)
3. Network-forming collagens (IV, VII, X)
4. Membrane anchored collagens (MACITs) (XIII, XVII, XXIII, XXV)
5. Short collagens (XXVI, XXVIII)
Types I, III, and V, predominantly produced by fibroblasts, are essential for 
the structure of the interstitial matrix. Their function as a pericellular “glue and 
structure” is necessary in tissue repair. Type IV is primarily located in the basement 
membrane and underlying epithelial or endothelial cells, ensuring their specialized 
polarization and function. Type IV collagen is the main constituent of basement 
membranes in tissues such as the lung, kidney, skin, intestine, and liver. It is mainly 
produced by endothelial and epithelial cells, and seen as intelligent collagen neces-
sary for tissue repair processes that allow polarized cells (endothelial and epithelial) 
to survive and function, enable regular tissue function [6, 13].
2.2 Proteoglycans
Proteoglycans are the functional modifiers of ECM and provide additional 
properties. They are proteins characterized by being covalently linked to glycosami-
noglycans (GAGs). These GAGs are long, negatively charged chains conferred by 
sulfate and carboxyl groups (heparan sulfate (HS), dermatan sulfate, and keratan 
sulfate (KS). The addition of sulfate and carboxyl groups to GAGs gives them this 
negative charge, enabling them to sequester water and cations (sodium and cal-
cium) and have cellular lubrication and filling functions, Figure 1 [6, 12, 14].
There are about three dozen extracellular matrix proteoglycans encoded in 
mammalian genomes, divided into several families. The two largest families include 
the LRR (leucine-rich repeat) proteoglycans and the hyalectans (such as versican). 
In addition to those mentioned, perhaps the most significant of all is perlecan 
(HSPG2), a multidomain protein that is part of all basement membranes. There are 
also two small families of transmembrane proteoglycans: glypicans and syndecans, 
both of which have heparan sulfate side chains, as does CD44 [12, 14].
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Syndecans are encoded by four different genes and represent the most abun-
dant transmembrane heparan sulfate proteoglycans (HSPGs). Their core protein 
comprises an extracellular domain, a single transmembrane domain, and a short 
cytoplasmic domain that interacts with the cell cytoskeleton. Glypicans are 
encoded by six different genes and are anchored to the cell membrane via glyco-
sylphosphatidylinositol (GPI). The multiple organs of the human body contain 
different isoforms of HSPG with various polysaccharide compositions and sulfation 
patterns [12, 15].
The extracellular domain of syndecans is intrinsically disorganized, a feature 
that allows it to interact with a huge variety of molecules and perform a wide 
variety of biological functions. Some of these functions involve acting as co-
receptors for tyrosine kinase receptors linked to growth factors. The HS chains of 
these proteoglycans share various ligands, such as matrix proteins, growth factors, 
cytokines, and chemokines, which are presented to high-affinity receptors present 
on the cell surface [3, 4, 6, 10].
In conclusion, proteoglycans are highly variable in their shape and structure 
to exert different functions in the ECM, i.e., and they are highly pleiotropic. This 
characteristic makes them essential in maintaining a healthy ECM, and without 
them, its entire structure would collapse.
2.3 Laminins
Laminins are trimeric glycoproteins formed by α, β, and γ chains often found 
in the basal lamina and mesenchymal compartments. The three chains form a 
coiled α-helical structure that builds the long arm, while the three short arms are 
each composed of one chain. At the end of the long arm are five laminated G-type 
(LG) domains of the α-chain that serve as binding points for the cell. Integrins, 
dystroglycan, lutheran glycoprotein, or sulfated glycolipids bind to these LG 
domains. At the end of each short arm are the N-terminal laminin (LN) domains 
that are important for laminin polymerization and the formation of the basement 
membrane [5, 6, 11].
Laminins have cell-specific functions such as adhesion, differentiation, 
migration, maintenance of phenotype, and resistance to apoptosis (anoikis). By 
binding to integrins, laminins can create a dynamic link between the cell and the 
ECM. The unique heterotrimeric laminins have the integrins as anchored partners 
allowing the induction of signaling pathways and the organization of the intracel-
lular cytoskeleton. It has been observed that heparan sulfates directly mediate the 
interaction between laminins and collagen IV. Laminins play crucial roles in both 
basal membrane formation and interactions between cells and the ECM. While 
collagen, proteoglycans, and hyaluronic acid constitute the main structural com-
ponent of the MEC, laminins are one of the molecules that bridge the cell-ECM 
interaction gap [6, 11, 12, 14].
2.4 Fibronectin
Fibronectin is a high molecular weight protein composed of two subunits linked 
together by two cysteine persulfide bonds. It is secreted in a soluble form by hepato-
cytes into the bloodstream or expressed in tissues by fibroblasts, forming a fibrillar 
network. The structure of fibronectin and its multiple post-translational modifica-
tions result in an immense variety of interactions with various ECM components 
(growth factors and GAGs) that mediate cell attachment and motility, ECM 
remodeling, host-pathogen interactions, among others. A single gene encodes this 
glycoprotein with 20 human isoforms resulting from alternative mRNA excisions 
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(primary transcript). Similar to collagen, fibronectin forms a fibrillar network in 
the ECM. The structure of the fibronectin matrix is mediated by selective binding 
to α5β1 integrins. Compact, soluble fibronectin is secreted and unfolded through 
these integrins, revealing specific binding sites for other fibronectin molecules to 
form its fibrillar network. Binding to fibronectin induces integrin aggregation, 
which provides high local concentrations of fibronectin on the cell surface. This 
phenomenon promotes fibronectin–integrin interactions through the N assembly 
domains of each molecule [5, 6, 16].
Once fibronectin is attached to the cell surface by integrins, the actin cytoskel-
eton can drag molecules to the fibronectin to change its conformation. This will 
affect the C-terminal regions of fibronectin, revealing binding sites for fibro-
nectin, heparan sulfates, heparin, collagen, and other ECM molecules. Through 
strong non-covalent protein–protein interactions, the fibronectin network 
matures and becomes insoluble, although other ECM proteins can mediate mature 
lateral interactions between fibrils. These interactions stabilize the relatively 
weaker binding sites [5, 6, 16].
In conclusion, fibronectin works as a skeleton upon which the bioavail-
ability and activity of various growth factors are orchestrated. The interaction 
of fibronectin with growth factors (e.g., TGF-β, PDGF, HGF, VEGF, FGF) can 
impact cell migration, cell proliferation, survival signals, and angiogenesis as 
downstream outcomes of their activation through mechanical or enzymatic 
activation [5, 6, 14, 16].
3. Functions of the extra cellular matrix
The countless unique molecules that are part of the constitution of ECM give 
it various functions that simultaneously influence biochemical and biophysi-
cal processes in the cell. Although ECM was for many years considered an inert 
component that only provided structure to cells in tissue formation, its role in 
determining cellular functions and phenotypes has been clarified in the last two 
decades [2, 6, 14, 17].
The many proteolytic processes that modify ECM, by the action of proteolytic 
enzymes, play roles in ECM remodeling and are thought to release ECM-binding 
growth factors and expose cryptic activities in ECM, including the release of anti-
angiogenic factors. Similarly, enzymes that degrade GAGs, such as heparanases and 
sulfatases, can also change the properties of proteoglycans in the ECM. Remodeling 
of the ECM by these various processes has important effects on development and 
associated pathologies [2, 14, 17].
Finally, ECM is known to transmit mechanical signals to cells and activate 
intracellular signaling mechanisms and the cytoskeleton machinery. The impor-
tance of ECM and its varied functions in the development and maintenance of 
cellular balance or homeostasis is indisputable [2, 14, 17].
3.1 Migration and proliferation
Cell migration is essential for tissue development, a fact demonstrated by neural 
crest cells, which migrate from the periphery of the neural tube to different parts of 
the embryo to form the heart, nerves, skin, and skull [2, 6].
The ECM influences the path and speed of migrating cells through its topog-
raphy, composition, and physical properties. Cells migrate from regions with 
low ECM concentration to high ECM concentrations due to an adhesion gradient 
called haptotaxis. Proteases that degrade ECM also play a facilitating role in cell 
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migration through a process involving matrix metalloproteinases (MMPs), their 
inhibitors, among other enzymes. It is essential to realize that constant remodel-
ing of the ECM occurs during development [2, 4, 6].
3.2 Development
The topographic variation in the structure and elasticity of ECM provides cells 
with the ability to adapt and form complex morphological systems that are essential 
for different organs [2, 4, 6].
ECM modulates tissue growth to form complex structures that are necessary 
for these organs to function. In addition, it provides structural organization 
not only through its action as a physical barrier to cell growth and by activating 
intracellular signaling in a time- and context-dependent manner. ECM exerts this 
effect by modulating the distribution of growth factors, physical anisotropy, and 
anchoring [2, 4, 6, 11].
ECM also has an essential role in highlighting the influence on cell fate. This role 
is shown in mammary gland differentiation. Even with hormonal stimulation in 
vitro, mammary gland cells do not secrete milk proteins. However, after exposure 
of these cells to laminin-1, they begin to secrete these proteins. This phenomenon 
indicates to us that an appropriate ECM microenvironment is indispensable for the 
cell to be able to fulfill its functions [2, 4, 6].
To conclude, cells can sense the physical properties of the adjacent matrix 
and activate the appropriate intracellular mechanisms for their differentia-
tion. Therefore, the physical properties of the ECM have cell differentiation 
capabilities.
3.3 Tissue homeostasis
ECM is a highly dynamic structure. Even after development, ECM is constantly 
being deposited, degraded, and modified to maintain tissue homeostasis. This is 
especially important for preserving cell phenotype and physiological processes such 
as wound healing, angiogenesis, and bone remodeling [2, 4, 6].
To maintain tissue homeostasis, cells in contact with the ECM perceive ECM 
properties through receptors and adhesion complexes. In turn, the cell regulates the 
expression of ECM components and enzymes based on the signals it receives. This 
leads to a feedback mechanism in which cell also influences ECM, resulting in a 
balance of deposition and degradation of ECM components [2, 3, 6].
The response of cells to other stimuli is ultimately influenced by the ECM 
components. The complexity and importance of the feedback mechanism between 
the ECM and the cell is essential to maintain tissue homeostasis [2, 3, 6].
The imbalance in ECM deposition and degradation leads to disease and is a 
hallmark of cancer and other conditions that course with fibrosis. Overall, the role 
of ECM in tissue homeostasis is to direct the appropriate cellular response and 
phenotype to maintain mechanical integrity and tissue function [6].
4. ECM disruption in cancer progression
Traditional views of cancer have been changing, and the significant role of 
ECM in the regulation of cell proliferation, migration, and apoptosis have been 
highlighted. At the microscopic level, the organization of ECM constituents forms 
a specific microenvironment that plays a critical role in tumor progression. ECM is 
constantly remodeling and actively influences cell adhesion and migration. Thus, 
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small changes in the homeostasis of the microenvironment can result in significant 
effects on cancer cell proliferation. As the main component of ECM, collagen, 
dictates the main properties of the matrix, changes in its deposition or degradation 
can lead to loss of ECM homeostasis [2–4, 6, 11].
As cancer cells proliferate, the surrounding matrix changes a dynamic interac-
tion between cells and the microenvironment. Changes such as increased fibronec-
tin secretion, collagen type I, II and IV, indicate that tumor progression requires 
continuous interaction between the ECM and tumor cells. Increased deposition of 
matrix proteins promotes tumor progression as it interferes with cell–cell adhe-
sion, cell polarity, and the amplification of growth factor signaling. High collagen 
deposition has been shown to result in tumor progression through increased 
integrin signaling [6].
The increased stiffness of the matrix activates integrins as well as cytoskeletal 
tension, promoting cell adhesion and motility [2–4, 6, 11]. It has been observed 
that local cell invasion of tumors is directed along collagen fibers aligned, suggest-
ing that this linearization of the fibers facilitates invasion. These densely aligned 
collagen fibers are believed to act as cues for proliferating neoplastic cells to migrate 
outward from the tumor [2–4, 6, 11].
Tumor tissue hydration also has some impact on ECM dysregulation. Since it 
is strongly influenced by specific tissue GAGs due to their anionic structure and 
their ability to attract water, it is known that as hydration increases, the increase 
in intra-tumor hydrostatic pressure also increases, altering the biomechanical 
properties of the tissue that are known to be crucial for invasion [2–4, 6, 11].
Elevated levels of hyaluronic acid (carboxylated and free glycosaminoglycan) in 
ECM correlate with an increased likelihood of malignancy and poor prognosis. As 
a ubiquitous linear polysaccharide, hyaluronic acid (HA) is fundamental in deter-
mining the compressive properties of most biological tissues. Combining tensile 
strength due to collagen conformation and compressive strength due to hyaluronic 
acid creates the ideal biophysical properties for tissue homeostasis. Furthermore, 
hyaluronic acid is an induction signal for epithelial-mesenchymal transition (EM) 
and a migration substrate. It is also important in regulating vascular endothelial 
barrier permeability by stabilizing cell–cell junctions [2–4, 6, 11, 18].
Although increased levels of collagen directly promote ECM stiffness and 
mechanistically drive cell motility and proliferation, the exact role of hyaluronic 
acid in cancer metastasis remains unclear. However, its downregulation may serve 
as a key biomarker for invasion and metastization [2–4, 6, 11, 18].
5. Human papillomavirus (HPV)
5.1 The virus
The human papillomavirus (Human papillomavirus-HPV) is a small (55 nm) 
non-enveloped virus that belongs to the Papillomaviridae family. It can be classi-
fied according to its tropism (cutaneous, mucocutaneous, and mucosal). Since the 
availability of cellular factors expressed in different layers of the epithelium plays 
a role in viral gene expression and genome amplification, the viral cycle is strictly 
dependent on the epithelial differentiation program HPV infections are associ-
ated with some hyperproliferative pathologies of epithelia and mucosa, and most 
cervical cancer and warts cases. It has been described more than 200 types of HPV. 
Almost 40 types exhibit a particular tropism for the anogenital region’s cellular 
floor epithelium and mucous membranes. HPV types in this subgroup are classified 
as being of high or low oncogenic risk, depending on the clinical lesions they cause. 
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The high-risk HPV types are associated with almost all cases of cervical cancer, 
and the low-risk HPV types are the cause of nearly all anogenital warts and low-
grade lesions with a slight tendency for malignant progression. The most prevalent 
high-risk HPVs are HPV16 and HPV18, while the most common low-risk types are 
HPV6 and HPV11. Infections with specific high-risk HPV types are etiologically 
related to a significant proportion of vulvar, vaginal, anal, penile, and head and 
neck carcinomas [19–22].
5.2 Structure of HPV
HPV is a double-stranded circular DNA virus with 6.8–8.4 kb and can be divided 
into three functional regions:
• Early region (E-early), consisting of the early genes (E1-E8) that encode the 
replication proteins and regulate the different phases of the viral cycle.
• Late region (L-late) consisting of the L1 and L2 genes that encode the capsid 
proteins. L1 is called the major capsid protein and is responsible not only for 
the specific adhesion of the virus to the cell but also for the immune response 
produced by the host against this virus. L2, the minor capsid protein, appears 
to be important in the encapsidation of viral DNA [23].
• The long control region (LCR- long control region), consisting of regulatory 
genes, contains the origin of replication and the E6 and E7 genes that control 
transcription and regulate the expression of different HPV genes [19, 24].
The two oncogenes, E6 and E7, play a major role in carcinogenesis, contribute 
to immortalizing normal human keratinocytes in cell culture systems, and are 
essential to maintain the transformed phenotype in vivo. The main role of these 
proteins during the HPV cycle is to generate a permissive cellular microenviron-
ment for viral replication. This includes the induction of DNA replication machin-
ery, immune evasion, and the downregulation of apoptosis. To achieve this, the 
E6 and E7 proteins give rise to critical cellular regulatory pathways, including 
those dominated by p53 and pRb. The E6 protein (16–19 kDa) associates with 
p53 (tumor suppressor protein) and promotes its degradation. E7 (10–14 kDa) 
inactivates the function of another tumor suppressor protein, the retinoblastoma 
protein (pRB). Together, these two proteins promote the mechanisms involved in 
the genesis of tumors caused by these viruses, favoring cell transformation and 
immortalization [19, 24].
5.3 Viral replication
As already described, the life cycle of this virus is synchronized with cell dif-
ferentiation and division.
Whether or not the viral life cycle is complete depends on the nature of the 
epithelial site where infection occurs and external factors such as hormones and 
cytokines. It is suggested that infection requires access to the viral particles (com-
posed of viral DNA and the capsid proteins, L1 and L2) to the basal lamina and 
their interaction with HSPGs laminin [23]. Structural changes in the virion capsid 
facilitate transfer to a secondary receptor in the basal keratinocyte, necessary for 
virus internalization and subsequent transfer of the viral genome to the nucleus. 
Once internalized, virions undergo endosomal transport and pass into the nucleus, 
where the capsid disassembles and DNA release occurs. The L2-DNA protein 
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complex ensures the correct nuclear entry of the viral genomes, while the L1 
protein is retained in the endosome and ultimately subject to lysosomal degradation 
[20, 23, 24].
Infection is thought to require an epithelial wound or micro-wound to allow 
the virus access to the basal lamina. Indeed, active cell division, as occurs during 
wound healing, is required to enter the virus genome into the nucleus. It has been 
proposed that lesion formation requires the initial infection of a mitotically active 
cell [19, 20].
It is also known that in the basal cells of the epithelium, the expression of viral 
genes is repressed and expression of early (E) and late (L) genes only happens at 
the level of keratinocytes or the upper mucosal layers. Viral replication is associated 
with excessive cell proliferation of all epidermal layers except the basal layer. Since 
the basal cells of the stratified sidewalk epithelium are the only ones capable of 
dividing, they are the initial target of HPV infection [19, 20, 23].
Regardless of the nature of the infected basal cell, infection is followed by an 
initial phase of genome amplification and then the maintenance of the viral episode 
at a low copy number. The viral replication proteins E1 and E2 are considered 
essential for this initial amplification phase. The precise role of the HPV E6 and E7 
proteins in infected basal cells is uncertain, particularly for low-risk HPV types that 
are not generally associated with neoplasia and whose viral DNA does not integrate 
into the chromosomes. They are thought to produce lesions following infection of 
a basal stem cell at the site of a wound. The role of the curative response in driving 
the initial proliferation of the infected cell may well be critical, with local microen-
vironment signaling influencing viral gene expression and/or protein functions. In 
the case of high-risk types that cause neoplasia, there is the integration of the viral 
genome into the chromosomal DNA, and the role of the viral E6 and E7 proteins 
in cell proliferation in the basal and parabasal cell layers is quite clear, especially at 
cervical sites where neoplasia can occur. It is clear that many functional differences 
exist between high- and low-risk E6 and E7 proteins and that these contribute, 
along with differences in promoter activity and gene expression patterns, to the 
different HPV-associated pathologies seen in vivo. Indeed, recent studies have 
suggested that a critical event in determining the neoplastic grade is the down-
regulation of E6/E7 expression, even in the absence of genome integration, which 
is classified according to the extent to which basal-like cells extend into suprabasal 
epithelial layers. While such functional differences undoubtedly contribute to the 
respective abilities of high and low-risk HPV types to cause neoplasia and cancer, 
it is important to remember that a key function of the E6 and E7 proteins in most 
HPV types is not to promote basal cell proliferation but rather to stimulate cell cycle 
re-entry into the middle epithelial layers to allow genome amplification [19, 23, 24].
6. HPV-MEC interaction
As previously mentioned, the role of HSPGs in HPV infection is quite relevant 
[15, 25].
The HSPGs typically consist of a core protein and GAG chains. The core protein 
of syndecans is composed of an extracellular domain, a unique transmembrane 
domain, and a short cytoplasmic domain that interacts with the cytoskeleton. The 
glypicans are GPI-labeled HSPGs. The GAG chain comprises unbranched anionic 
polysaccharides composed of repeated disaccharide units formed by sulfated uronic 
acid and hexosamine residues [15–18].
As components of the ECM, HSPGs contribute to the organization of the 
basement membrane and mediate cell adhesion and motility. HSPGs bind to 
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cytokines, chemokines, and growth factors on the cell surface, preventing their 
degradation, creating temporary storage sites or morphogen gradients important in 
development. Still, on the cell surface, they also serve as endocytosis receptors, and 
regulate the lysosomal degradation of extracellular molecules and provide nutrients 
to the cells. In addition, they are involved in the endocytosis of cell receptors. They 
mediate the transcellular transport of chemokines through endothelial cells. They 
also serve as co-receptors for a fibroblast growth factor (FGF) and its receptor. 
They mediate intracellular signaling or intracellular stress through the proteolytic 
shedding of syndecans and play an important role in developing and maintaining 
stem cell niches [15, 18].
The strategic localization of HSPGs in tissues is critical to their functional role. 
The localization of SDCs and GPCs at the plasma membrane regulates intracellu-
lar and cell-to-ECM signaling. The localization of HSPGs in the basement mem-
brane regulates their barrier functions and coordinates cell–cell and cell-MEC 
interactions [15, 18].
Degradation of heparan sulfate chains by heparanase produces heparin-like 
fragments that activate FGF-2 mitogenicity. Therefore, the biological role of an 
HSPG depends on the properties of its core protein, the number of GAG chains 
attached, its location in cells and tissues, and the biosynthetic modifications that 
its GAG chains receive in situ. A wide range of biological functions is attributed 
to GAGs in cancer metastasis and other biological events due to their controlled, 
highly heterogeneous, and complex structure that allows for the regulation of 
tissue-specific functions [15, 18].
6.1 HSPGs as viral receptors
HSPGs are receptors hijacked by numerous viruses to bind to host cells. This 
typically occurs through electrostatic interactions between the negative charges 
of HSPGs and the basic amino acid portions of viral surface proteins. A consistent 
amount of data supports the natural dependence of HSV, DENV, and HPV on 
HSPGs for their binding to host cells [15, 26].
HSPGs, due to highly sulfated GAG chains, exhibit an overall negative charge 
that can interact electrostatically with the basic residues of viral surface glycopro-
teins or viral capsid proteins of non-enveloped viruses. Viruses exploit these weak 
interactions to increase their concentration on the cell surface and increase their 
chances of binding to a more specific entry receptor. HSPGs directly serve as entry 
receptors in rare cases, as described for herpes simplex virus (HSV)-1. Another 
study showed that HSPGs are crucial for SARS-CoV entry. Prophylactic treatment 
with bacterial heparinase I or heparin showed a reduction in SARS-CoV infectiv-
ity. Thus, either loss of HS or competitive inhibition confers some protection to 
cells against SARS-CoV. Given the structural similarities between SARS-CoV and 
the novel SARS-CoV-2, it would be interesting to study the effects of removing HS 
on SARS-CoV-2 infections. There are multiple ways to reduce viral contact with 
cell surface HS (HPSE, heparinase, heparin, soluble HS, and MMPs), investigat-
ing that this binding may give insight into SARS-CoV-2 entry and possible thera-
peutics [15, 26, 27].
All papillomaviruses are believed to rely on HSPGs for their initial binding. 
However, HPV-16 is the serotype whose pathogenesis is most studied due to its 
oncogenic potential and prevalence [15].
As already mentioned, the HPV infection cycle starts from the basal mem-
brane of the vaginal mucosa, exploring abrasions or lesions in the epithelium 
(Figure 2A and B). The entry of HPV particles into host cells is a multistep 
process that begins with binding to HSPGs expressed on the cell surface of basal 
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keratinocytes or in the ECM. The interaction of the HPV16 L1 capsid protein with 
the HS chains of proteoglycans is well known but generally considered to have a 
passive role in infection. Binding to HSPGs induces conformational changes in 
the capsule and facilitates proteolytic cleavage of L1. This cleavage allows interac-
tions between capsid and cyclophilin B, which results in further conformational 
changes that expose the N-terminus of L2. The exposed N-terminus contains a 
conserved consensus cleavage site for the extracellular proprotein furin conver-
tase. This interaction is essential for successful HPV infection since cleavage of 
furin results in the exposure of a binding site on L1 postulated to be recognized 
by an unknown receptor. The described changes in virion conformation further 
facilitate the reduction in binding affinity to HSPGs, thus facilitating binding 
to the unknown receptor(s). These findings underscore the role of initial HSPG 
attachment to facilitate the critical step of L2 cleavage by furin and association 
with the putative second receptor for entry. Cleavage of furin has also been 
implicated in successful endosomal escape before transporting the viral L2/ADN 
complex into the nucleus, emphasizing the necessity of furin cleavage for success-
ful HPV infection [15, 20].
Syndecan-1, the most abundant HSPG in keratinocytes, plays an important role 
in this initial binding due to its expression in epithelial cells and its overproduction 
during wound healing. It has been shown that syndecan-1 when released plays a 
major role in the infection of keratinocytes by HPV. Instead of separating it from 
its HS chains, HPV particles are released from the cell surface through the normal 
process of HSPGs, remaining bound to HS chains (heparan sulfate) and growth 
Figure 2. 
Schema of the role of HSPGs in HPV16 infection. (A) Bottom is a normal cervix epithelia disrupted. Upper 
figure represents the details of wounded tissue healing mechanism, (a) MMP/ADAM cleaved GF (growth 
factor) bound to HSPG of cell membrane and also to the complex with laminin (b) shedd HSPG/GF complex, 
bounds to (c) adjacent cells GFR/EGFR as a co-receptor. (B) In bottom of figure HPV16 infected wound tissue 
release, as shown in upper figure, HPSE (heparanase) and HPV16 (a), HPV16 is coated with HSPGs and 
HS (heparansulfate) released respectively by MMPs/ADAM and HPSE, (b), HPV16 bounds to the complex 
HSPG-laminin in ECM, (c) adjacent keratinocytes through membrane EGFR-RTK and HS receptor bound 
as a complex (d) is endocytosed by the cell (e). (C) HPV16 integration by the infected keratinocytes during 
wound healing, after endocytosed in (B), progresses through CIN I, CIN II and CINIII to invasive cancer, after 
expression of E6 and E7 HPV oncogenic proteins.
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factors. They can bind to the epidermal growth factor receptor (EGFR). The 
specificity of growth factors is the bridge for the interaction of the virus with cel-
lular receptors, for example, tyrosine kinase, whose signaling promotes infection 
Figure 2A and B [15, 28].
Considering the biology of HSPGs, it stands to reason that HPV particles bound 
to HSPGs would associate with ECM, and indeed, free syndecan forms bind tightly 
to ECM via their HS chains. Many studies have shown that HPV particles accumu-
late in the ECM, and LN-332, a component of the ECM, is a proposed attachment 
factor for HPV. There is already evidence of direct protein–protein interaction 
between HPV16 and LN-332 Figure 2A and B [15, 25, 28].
Thus, HS chain cleavage enzymes are known to increase the release and infec-
tivity of HPV particles bound to ECM, indicating that many virus particles bind 
to ECM via these HS chains. Free syndecan-1 interacts with HPV16 and LN-332, 
demonstrating it to be an ECM-binding factor for HPV16, in addition to its role 
in binding HPVs to the plasma membrane. The interaction of snd-1 with LN-332 
is expected based on reports demonstrating the concentration in the EMC of free 
snd-1 with its native HS chains and that LN-332 binds plasma membrane resident 
snd-1 with high affinity and specificity through HS chains. LN-332 has been identi-
fied as a binding factor between ECM and HPV. Since LN- 332 intrinsically lacks HS 
chains but contains HS-binding domains, it seems more likely that HS chains bridge 
the gap between HPV and LN-332, and this could account for the co-localization in 
the ECM of HPV and LN-332 Figure 2A and B [15, 25, 28].
Models have been developed for explaining the mechanism of HPV release 
from HSPGs:
1. It is suggested that conformational changes in the structure of the virus capsule 
are caused by the binding of HSPGs, which then allows cleavage of the HPV L2 
protein, and subsequently triggers HPV release from binding factors that pas-
sively accumulate virus particles on their HS chains.
2. Based on the physiological processing of HSPGs molecules, HPV particles 
are released from the cell surface still in complex with HS and growth factors 
(GFs) and signal through GFRs to promote infection [28].
None of these models addressed ECM-bound virus release and infectivity. Still, 
a recent study suggested another model: high-speed processing of normal HSPGs 
from HPVs to gain infectious entry into keratinocytes. Inhibited viral release from 
ECM, cellular access, and infectiousness from ECM can be easily explained by this 
model. Proteases and heparanase play an essential role in HPV release from primary 
receptors [28].
This model, in which HPV usurps the processing of HSPGs and GFR/RTK 
signaling to promote infection, reflects the role of epithelial injury in mediating 
papillomavirus infections in vivo. Consequential breaks in epithelial damage result 
in an influx of HRs and cytokines involved in syndecan dissemination. Snd-1 
expression is enormously increased in keratinocyte migration and proliferation, 
and free syndecans present in wound fluids regulate the activity of GFs and MMPs. 
Thus, HPVs appear to have evolved to control the epithelial wound to gain access to 
mitotically active basal cells and take advantage of the factors and architecture that 
favor infection. Many intracellular pathogens of the female genital tract (HIV, her-
pesviruses, chlamydia, Neisseria) interact with cellular HSPGs. Thus, it is tempting 
to infer that these pathogens also appropriate the biology of HSPGs during infec-
tion. In summary, there is new knowledge about the transmission of oncogenic 
HPVs, and high-speed pathogens usually function during infection of their hosts. 
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These findings may point to additional targets for preventing HPV infections and 
potentially those of similarly acting pathogens Figure 2A and B [28].
Upon contact with HSPGs, the HPV capsid undergoes conformational changes 
assisted by extracellular cyclophilin B and cleavage of the capsid protein L2 by 
furin. This leads to a loss of affinity for HSPGs and binding to different secondary 
receptors. Identification of the internalization receptor is ongoing, but α6 integrins, 
EGFR, and the tetraspanin family may be involved. The entry kinetics of HPV 
appears to be asynchronous and slower than for most other viruses, but the cause is 
not yet fully known. Some research suggests that it may be linked to the cell cycle 
phase or the involvement of multiple receptors. Subsequently, the virus is internal-
ized through endocytosis, but there are conflicting reports on different HPV types 
and cells Figure 2A and B [15, 20].
The main goal in developing microbicides against HPV (or any viral infection) 
is to block the interaction between the virion proteins and the cell surface receptors 
used by the virus to gain entry into cells. As discussed earlier, the initial binding of 
HSPG is an important step for successful HPV internalization, as its inhibition has 
been shown to decrease HPV infection in vitro and in vivo. Since several different 
viruses use HS chains as the initial receptor/corrector to bind to the cell surface, 
it is considered a viable drug target, particularly about producing a microbicide 
with broad-spectrum protection against a range of HPVs (as well as other sexually 
transmitted viruses). Efforts in this direction will aid the development of antiviral 
drugs that are effective not only on many existing viruses but also on unpredictable 
emerging viruses [15, 20].
6.2 Pathogenesis and immunity
Once the basal layer of keratinocytes is reached, the virus can remain latent or 
take advantage of cell differentiation to replicate and initiate the disease. As for the 
host immune response, it is known that it can eliminate the infection or silence it 
(latent). The virus can persist with low infectivity, survive a weak immune response 
(persistence) and later induce pathology [19, 22, 24].
The mark of HPV infections is the effective evasion of innate immune recogni-
tion. The viral productive life cycle is exclusively intraepithelial, there is no viremia, 
no virus-induced cytolysis or cell death, and viral replication and release are not 
associated with inflammation. HPV globally decreases innate immune signal-
ing pathways in infected keratinocytes, and pro-inflammatory cytokines are not 
released, activation signals to Langerhans cells, cell migration from and recruitment 
of stromal dendritic cells (DCs) and macrophages are absent or inadequate [19, 24].
Despite the high impact of HPV protein expression on cellular homeostasis, 
these viruses are incomplete carcinogens. Therefore, further changes in the cell and 
its microenvironment are required for tumor establishment and progression. This 
process includes dysregulation of the ECM. In some cases, changes in the levels and 
activity of defined ECM components have been experimentally associated with the 
expression of HPV-specific proteins, suggesting the direct involvement of the virus 
in the downregulation of these factors. Other studies, mainly those performed with 
clinical specimens, have identified changes in the levels of ECM molecules during 
the progression of HPV-related diseases [21, 29].
7. ECM alterations in HPV-associated diseases
The natural history of cervical cancer development begins with a precursor 
lesion called cervical intraepithelial neoplasia (CIN). CIN 1 CIN 2 lesions are 
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classified as productive lesions, in which the viral cycle is complete. On the other 
hand, CIN 2 lesions and CIN 3 lesions are potential precursors of cervical cancer. 
The development of these lesions is mainly caused by persistent infection with 
oncogenic types of HPV. Intraepithelial lesions show low to moderate histological 
changes and may regress spontaneously within 1 to 2 years. In persistent high-risk 
HPV infections, high-grade precancerous lesions (CIN 2 and CIN 3) may develop 
within 3 to 5 years. Morphologically, CIN 3 (carcinoma in situ-CIS) represents 
a heterogeneous disease and can be considered a precancerous lesion of a more 
advanced cervical cancer Figure 2C [21, 30].
HPV infection has been associated with several changes in tissue organization 
and architecture, including downregulation of the expression and activity of 
MMPs. It has been shown that up-regulation of MMP-2 and MMP-9 expression 
and activity are associated with high-grade CIN, and their respective inhibitors 
have reduced expression levels in these lesions  
[4, 21]. On the analysis of MMP-11 and MMP-12 expression in high- and low-grade 
lesions, it was shown that both might be associated with the appearance of cancer 
precursor lesions and suggested that increased expression of these proteins may be 
considered an early event during the development of preneoplastic cervical lesions 
Figure 2C [21].
Alterations in other components of the ECM have also been explored in the  
context of cervical tissue transformation. Expression of the 67-kDa laminin recep-
tor (LR67) was found to progressively increase with CIN grade. LR67 is associated 
with CIN 2 to 3 and can be considered a marker of cell proliferation in cervical tis-
sue. These authors also demonstrated that combined analysis of LR67 and vascular 
endothelial growth factor-C (VEGF-C) could improve the clinical detection of 
high-grade CIN Figure 2C [21].
HPV infection has also been linked to a percentage of lesions in other epithelia 
of the anogenital tract, including the vulva, vagina, and anus. Vulvar, vaginal, 
and anal cancer precursor lesions are called vulvar intraepithelial neoplasia 
(VIN), vaginal intraepithelial neoplasia, and anal intraepithelial neoplasia (AIN), 
respectively. As with cervical precursor lesions, VIN and AIN also progress 
through degrees of epithelial transformation. The analysis of the expression of 
MMP-2, MMP-9, TIMP-1, and TIMP-2 by IHC in samples of VIN 1, 2, and 3 and 
invasive vulvar carcinoma suggested that overexpression of MMP-2, MMP-9, and 
TIMP-2 proteins may be related to the progression of VIN to invasive carcinoma 
Figure 2C [21].
8. ECM composition in HPV-associated cancers
The loss of regulation of ECM remodeling by unbalanced proteolysis plays a 
significant role in the loss of tissue homeostasis and pathological processes such 
as cancer. In cancer, this event may impact tissue tension and release chemotactic 
fragments of ECM components that influence the local microenvironment. It 
promotes cell migration and recruitment of stromal, endothelial, and immune 
cells to the tumor vicinity. The heterogeneous association of cancer cells and other 
elements observed in the tumor microenvironment, such as inflammatory infil-
trate, endothelial cells, and tumor-associated fibroblasts, should also be explored to 
understand ECM remodeling changes fully [4, 21].
The most investigated proteases present in this process are the MMPs, as 
described previously. These MMPs play a central role in basement membrane 
breakdown and cell invasion and neoangiogenesis, and metastasis. Excess MMP 
activity generates topographical changes in the tumor microenvironment through 
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modifications associated with proteolysis of the structural skeleton of the ECM. 
Indeed, linearization and thickening and/or degradation of specific collagen are 
common events observed in areas of epithelial tissue adjacent to tumor-associated 
blood vessels where cancer cells invade. The activity of MMPs also regulates cell 
migration and release of ECM fragments with biological functions, such as growth 
factors. The crucial role of specific MMPs in the process of carcinogenesis has set 
an objective task for researchers to explore the potential of MMPs as therapeutic 
targets. However, the use of broad-spectrum MMPIs offered no clinical advantages 
due to dose-limiting side effects [4, 21, 31].
Several authors have studied ECM alterations in both structural and remodeling 
molecules in invasive cervical cancer. More specifically, changes in the expression/
activity of galectins, collagens, proteoglycans, laminins, fibronectins, integrins, 
proteases, and regulators have been observed in cervical cancer samples derived 
cell lines [21].
The claudins (CLDNs) and occludins are families of proteins associated with 
tight junction establishment, epithelial cell polarity, and intercellular permeability. 
The expression levels of CLDN type 1, 2, 4, and 7 proteins are increased in HSIL 
lesions and invasive cervical tumors when compared with normal cervical tissues. 
On the other hand, occludin is expressed in the basal cell layer of normal cervical 
tissues. Its protein level is reduced in invasive cervical carcinomas compared with 
CIN samples. Thus, changes in cell adhesion and ECM structure are a common early 
feature in cervical cancer progression [21].
Expression of the high-affinity laminin-binding protein 67-kd (67LR) has also 
been shown to increase both CIN and cervical cancer samples compared to normal 
cervical tissues.
Versican, an ECM proteoglycan, was evaluated in cervical cancer samples by 
IHC (Immunohistochemistry) and situ hybridization (ISH). Expression of high 
levels of versican in tumor stromal myofibroblasts was associated with a lower 
frequency of CD8-positive T cells, more significant invasion and depth of tumor 
parametrial infiltration, and no change in cervical cancer survival. Interestingly, 
the beta-galactoside- galectin-1 binding protein was more expressed in stromal cells 
adjacent to cancer when compared to normal stroma associated with the cervical 
tissue. Furthermore, a higher expression level of galectin-1 was associated with 
increased local tumor recurrence and poor cancer-specific survival in patients with 
stage I-II cervical tumors after radiation treatment. However, it could not predict 
distant metastasis [21].
Laminin-1 and smooth muscle actin proteins (SMA) showed increased expres-
sion, mainly in the surrounding cervical tumor stroma compared to the normal 
cervical stroma. In addition, tumor cells especially expressed laminin integrin a6b4 
receptors, and tumor-associated fibroblasts showed higher levels of laminin-a1 and 
laminin-b1 and lower levels of laminin-5, fibronectin, collagen III, TIMP-1, and 
the hyaluronic acid receptor CD44 when compared to normal fibroblasts. Finally, 
MMP-7 and MMP-9 expression has been shown to correlate with CD44 expression 
in skin cancer cells [21].
The data discussed above show that ECM composition and function altera-
tions are common in HPV-associated lesions and cancers. Taken together, these 
changes highlight the complex molecular pathways that lead from initial infec-
tion to disease. For example, analysis of the impact of HPV on components of 
the MMP family has produced a spectrum of data that could be used for disease 
diagnosis and identification of targets for therapy. The data summarized here 
also show that, concerning the mechanisms by which HPV modulates MMP 
expression and activity, there is still much to learn. Finally, alterations in the 
ECM may impact the microenvironment of HPV-infected tissue, affecting the 
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recruitment of inflammatory infiltrates, altering the fate of different cell popu-
lations present in the tumor, and ultimately determining disease progression and 
prognosis [4, 21].
More studies are needed to understand how HPV proteins affect the dynamic 
balance of the ECM in associated pathologies. This will help us to understand the 
disease genesis and define more appropriate clinical interventions. Importantly, 
the vast majority of the ECM changes described have also been observed in 
HPV-independent tumors. Therefore, understanding the virus-mediated 
molecular events that lead to ECM disruption may be useful for understanding 
the basic mechanisms of carcinogenesis and developing more general antitumor 
approaches [21, 32].
8.1 Heparanase and heparan sulfate/syndecan-1 axis
As mentioned earlier, syndecans are a family of four HSPGs that can be soluble 
or membrane-anchored. Syndecan 1 (SDC-1) is the one that has been most studied 
and is found mainly on the surface of epithelial cells. Loss of syndecan-1 and 
E-cadherin from the cell surface is known to be a critical step in the transition to 
epithelial neoplasia [18, 33].
The heparanase/SDC-1 axis is a key point regulating cell signaling when tumor 
cells are present and in their respective microenvironment. This heparanase/SDC-1 
axis modulates cell proliferation as it regulates hepatocyte growth factor (HGF) 
and vascular endothelial growth factor (VEGF). HGF is a cytokine that increases 
the growth, motility, angiogenesis of tumor cells. Free syndecan-1 binds to secreted 
HGF and ultimately facilitates a paracrine and autocrine signaling cascade through 
the cellular receptor c-Met. It binds to syndecan-1 in the ECM, stimulating angio-
genesis and tumor invasion via the Erk pathway secreted VEGF. To regulate gene 
expression, heparanase and syndecan-1 can also be transported to the nucleus to 
regulate gene expression. Overall, nuclear HS chains and syndecan-1 are considered 
anti-proliferative and decrease gene transcription. Specifically, highly sulfated 
HS chains are mostly inhibitory, contrasting with free syndecan-1 that promotes 
angiogenesis, proliferation, and cell invasion. Conversely, heparanase present in the 
nucleus increases gene expression and promotes growth. Thus, syndecan-1 expres-
sion is considered a prognostic tool in solid and hematologic malignancies. A high 
level of stromal expression of syndecan-1 is a negative prognostic factor, and low 
levels of epithelial expression are indicators of advanced disease and poor progno-
sis. Loss of syndecan-1 is believed to represent cancer cells with high malignant and 
metastatic potential [4, 17, 33].
9. Heparanase
Heparanase is an endo-β-D-glucuronidase that cleaves the side chains of HS. 
This results in the release of bioactive HS fragments from the ECM and in struc-
tural changes. Over the past two decades, much work has been dedicated to study-
ing the role of heparanase in cancer biology. Various analysis methods have revealed 
that heparanase expression is increased in numerous cancers, including hemato-
logical malignancies, carcinomas, and sarcomas. In addition, elevated heparanase 
levels are associated with reduced postoperative survival, increased angiogenesis, 
and metastasis. All of these factors have triggered the development of heparanase 
inhibitors as novel anti-cancer agents [4, 17, 33].
Mammalian cells express a single functional heparanase enzyme, heparanase-1. 
Heparanase-2, a homolog of heparanase, has been cloned but cannot perform HS 
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degrading activity. It can, however, regulate the activity of heparanase-1. The hepa-
ranase structure contains a TIM barrel fold, which incorporates the enzyme’s active 
site and a distinct C-terminus domain with non-catalytic properties and is involved 
in the non-enzymatic signaling and secretion function of heparanase [17, 33].
The expression of heparanase is under tight regulation. In non-cancer cells, 
the heparanase promoter is constitutively inhibited, secondary to promoter 
methylation and p53 activity, which suppresses heparanase gene transcription 
by binding directly to its promoter. In addition, further regulation occurs dur-
ing post-translational processing. Cathepsin L is required for post-translational 
activation of heparanase, and cathepsin L inhibitors prevent the formation of 
active heparanase. In non-pathological states, heparanase expression is restricted 
primarily to platelets, activated white blood cells, and the placenta with little or no 
expression in normal connective tissue or epithelium. In addition, it is most active 
under acidic conditions (pH 5–6), during inflammation, or within the tumor 
microenvironment [17, 33].
9.1 Role of heparanase in HPV viral pathogenesis
As already mentioned, increased expression of heparanase in numerous malig-
nancies is associated with poor prognosis. And the direct role of this enzyme in 
neoplasms was confirmed when inhibition/silencing of heparanase in cancer cell 
lines resulted in a significant reduction in the invasive phenotype of the cells [4, 33].
The primary enzymatic activity of heparanase in the cleavage of the HS side 
chains of HSPGs and consequent release of growth factors and cytokines give rise 
to cell signaling pathways capable of inducing ECM remodeling. Heparanase can 
also release proangiogenic growth factors bound to heparan sulfates such as bFGF, 
HGF, PDGF, and VEGF, from the extracellular matrix to promote endothelial cell 
migration and proliferation indirectly. Tumors with high levels of heparanase have 
significantly higher microvascular density than tumors with low levels of this 
enzyme [4, 33].
Several heparanase capabilities have been demonstrated in the progression of 
cancers. These include increased cell proliferation via insulin, increased resistance 
to chemotherapy, expression of mesenchymal markers, increased autophagy, 
increased cell adhesion, and even a procoagulant function [26, 33].
Focusing on human papillomavirus infection, we remain to understand what 
role heparanase plays in HPV viral pathogenesis. Recent studies show that HPV16 
particles bind to the ECM through HS chains. Reducing the activity of matrix 
metalloproteinases and heparanase drastically reduces the release of viruses from 
the ECM, which results in the loss of viral uptake and infection of human keratino-
cytes. On the other hand, exogenous heparanase promotes viral release and disease. 
This phenomenon may be necessary for explaining, especially at the wound site, the 
host healing response and RTK/GFR signaling that increases HS release, allowing 
an ideal environment for HPV to infect keratinocytes Figure 2B [3, 34].
Other research work has shown the significance of the HPV E6 gene in HPV-
heparanase interaction in head and neck squamous cell carcinoma (HNSCC). The 
HPV E6 gene interacts with p53, decreasing its activity, leading to increased expres-
sion of heparanase since p53 is a potent inhibitor of transcription of this enzyme; 
expression of p21, a downstream component of the p53 pathway, correlates positively 
with heparanase expression on tissue section staining, confirming the heparanase-
p53 signaling event. Polysaccharide segments of the HS chains serve as attachment 
sites for many growth factors, cytokines, chemokines, and various bioactive ligands. 
Cleavage of the HS chains by heparanase releases these bioactive factors increasing 
tumor invasion and malignancy in the case of HPV-induced HNSCC16 [3, 34].
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10. The potential of future targeted therapies
Current statistics on the prevalence of HPV and cervical cancer alone under-
score the need for alternative therapies to prevent and treat HPV infections. 
Existing HPV vaccines, while highly effective, do not offer protection against 
all high-risk HPV types, let alone low-risk HPV types. Furthermore, these vac-
cines are purely prophylactic and are not easily accessible to women in low- and 
middle-income countries (LMIC). For these reasons, alternative therapies that have 
broad-spectrum protection against HPV types, as well as other sexually transmitted 
infections, are worth exploring.
Since heparanase is an influential enzyme in tumor progression, it is the ideal 
therapeutic target. And since it is typically not expressed in healthy tissue, the side 
effects of its inhibition would be minimal. A series of heparanase inhibitors have 
been studied and produced, namely heparin, logically because it is a molecule close 
to HS. However, it is limited as an anti-cancer therapy because of its anticoagulant 
effects. Similarly, when LMWH (Low molecular weight heparins) was tried as an 
alternative for the same effect, but the results were controversial [4, 17, 33].
In addition to heparins, strategies have been developed to inhibit heparanase, 
such as HS mimetic molecules, modified heparins, etc. HS mimicking molecules 
have lower anticoagulant activity and greater selectivity for heparanase than hepa-
rin, allowing a wider therapeutic window. Some inhibitors already investigated are 
PI-88 (Mupaphosphat), PG545, SST0001 (Roneparstat), M402 (Necumparanib). 
In addition to HS mimetics, the non-steroidal anti-inflammatory aspirin, widely 
suggested to have a long-term anti-cancer effect, binds directly to the active site 
of HPSEs, inhibiting their enzymatic activity and preventing HPSE-dependent 
cancer cell migration, metastasis, and angiogenesis both in vitro and in vivo. As 
HPSE inhibition may seem attractive for cancer mitigation, it is important to note 
the critical role of the enzyme in the infiltration of activated NK cells in primary 
tumors and metastasis sites. Consequently, potential inhibitors must be highly 
selective and thoroughly investigated to limit adverse effects [4, 17, 33].
As we see, several heparanase inhibitors have entered clinical trials for various 
cancers, but none yet for viral diseases. Early results already suggest that using 
heparanase as a target may have rewarding benefits in controlling many viral infec-
tions, and thus the inhibitors listed above may have beneficial effects. Now, the 
promise that inhibiting this enzyme or the upstream effector, p65, could provide 
a novel therapeutic intervention to treat the disease. Overall, emerging knowledge 
about heparanase as an essential regulator of viral infections and associated mor-
bidities could one day make a broad-spectrum antiviral drug a real possibility [34].
11. Conclusion
In this paper, we have discussed the extracellular matrix’s very complex and 
important role in developing and progressing cancers and, more specifically, in 
human papillomavirus infection. Indeed, in recent years the ECM has been increas-
ingly considered a crucial component in physiological processes such as cell pro-
liferation, adhesion, and migration. The perspective of cancer and its progression 
has also changed. We no longer consider a disease caused only by dysregulated cell 
proliferation. Still, we give importance to the microenvironment and its changes 
and adaptations to cellular stress. In-depth knowledge of the ECM components, 
their complex interactions, and their constant and dynamic remodeling during all 
stages of tumor development brings some hope in developing promising targeted 
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therapies to combat these pathologies. Likewise, knowledge of the components of 
viral particles and host cell entry factors and their specific interactions may allow 
the design of efficient antiviral strategies [15, 22].
Indeed, the role of HSPGs in HPV interaction with the ECM is undisputed and 
developed throughout the work. The enzyme heparanase, which we know has a 
significant impact on tumor progression and metastasis. Thus, as the influence of 
the tumor microenvironment on cancer progression becomes more evident, the 
focus on inhibiting enzymes that degrade HSPGs highlights an approach to main-
tain normal tissue architecture, inhibit tumor progression, and block metastasis. 
This review addresses the role of these enzymes, namely heparanase, in the context 
of the tumor microenvironment and their promise as a therapeutic target for cancer 
treatment, particularly cervical cancer [15, 17].
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Acronyms and abbreviations
CD44 Cluster of differentiation 44
CIN cervical intraepithelial neoplasia
CLDN claudins
ECM extracellular matrix
EGFR/RTK epidermal growth factor receptor/ tyrosine kinase receptor
FGF fibroblast growth factor
GF growth factors
GFRs growth factor receptors
GPI glycosylphosphatidylinositol
HGF hepatocyte growth factor




HSIL high-grade intraepithelial lesion
HSPGs heparan sulfate proteoglycans
LN-332 laminin 332
LRR leucine-rich repeat
LSIL low-grade intraepithelial lesion
MMPIs matrix metalloproteinases
PDGF platelet-derived growth factor
SND-1 syndecan 1
TIMPs an inhibitor of type 2 metalloproteinases
VEGF vascular endothelial growth factor
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